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A G polymorphism in the CRBN gene acts as a biomarker of
response to treatment with lenalidomide in low/int-1 risk MDS
without del(5q)
Leukemia (2013) 27, 1610–1613; doi:10.1038/leu.2013.59
E3 ubiquitin ligase protein Cereblon (CRBN) has been identified as
a direct molecular target for the teratogenicity of thalidomide and
cytotoxicity of immunomodulatory drugs (IMiDs) such as lenali-
domide.1,2 CRBN gene is highly conserved and its related protein
of 442 AA is ubiquitously expressed in humans. CRBN is part of a
functional E3 ubiquitin ligase complex together with the DNA
damage-binding protein-1 (DDB1), Cullin 4A and Roc1, and acts as
a substrate receptor for client proteins to be ubiquitinated and
degraded by proteasome.1 CRBN itself undergoes auto-
ubiquitination, and thalidomide is described as an inhibitory
molecule for CRBN auto-ubiquitination activity.
Thalidomide or lenalidomide have demonstrated their efficacy
in the treatment of various hematological disorders including
myeloma3 and myelodysplastic syndromes (MDS), either with or
without deletion of 5q chromosome.4–6 It has been recently
shown that changes in gene expression patterns induced by
lenalidomide are abrogated by the depletion of CRBN gene in
myeloma cell lines.7 Furthermore, 485% patients with low
expression of CRBN are resistant to treatment with thalidomide,
and, conversely, high CRBN gene levels correlate with better
survival in myeloma patients treated with maintenance thalido-
mide.7,8 In low/int-1 risk MDS, the erythroid response rate to
thalidomide is quite low (16–30%) and responses are usually
short,9 whereas patients with low/int-1 risk MDS with del5q have a
high response rate (50–67%) to lenalidomide.5,10 By contrast,
430% of low/int-1 MDS patients without del(5q) respond to this
treatment.6,11 Altogether, these data provided us with a rationale
to investigate the role of CRBN gene in the response to
lenalidomide in low/int-1 MDS patients without del(5q).
Sixty-six MDS patients from five hematological centers with low/
int-1 risk MDS without del5q were included in this study between
January 2010 and December 2012. All patients were anemic and
resistant to erythropoiesis-stimulating agents either epoetin
alpha/beta (60 000 U/week) or darbopoetin (300 mg/week) during
12 weeks, and remained transfusion dependent (X4U of Red Blood
Cells during the previous 8 weeks). They received a dose of 10mg/
day of lenalidomide for 21 days every 28 days, and the erythroid
response rate, hematological improvement-erythroid was evaluated
according to the IWG 2006 criteria after at least 3 months of
treatment. Fifteen patients were not evaluable due to treatment
toxicity or early death. The characteristics of the 51 remaining
patients who completed 3 months of treatment (26 RARS, 8 RCMD-
RS, 7 RCMD, 4 RA, 5 RAEB-1 and 1 CMML) are described in Table 1.
Forty-one (80%) patients had a normal karyotype, five presented
with trisomy 8, two presented del11q and one had del20q.
Karyotype was unavailable for one patient. Comparisons using
Pearson w2 or Fischer’s exact test for qualitative data, and Wilcoxon
test for quantitative data were performed on Stata MP 12.1 software
(Ritme, Paris, France). All tests were two-sided and a Po0.05 were
considered to have statistical significance.
Fourteen (27%) patients were responders to lenalidomide,
according to IWG 2006 with 8 (57%) major responses and 6 (43%)
minor responses according to IWG 2000, and 37 (73%) were
nonresponders. No difference of age (P¼ 0.901), sex (P¼ 0.334) or
International Prognostic Scoring System (IPSS; P¼ 0.324) at
treatment onset was observed between the two groups. The
overall response rate was equivalent to that reported in the
literature.6,11
The CRBN gene located in 3p26.2 contains 11 predicted exons.
To address the putative role of CRBN in the response to
lenalidomide in MDS patients, we conducted genetic studies
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including comparative genomic hybridization (CGH) and Sanger
sequencing to search for deletion or mutation of CRBN gene.
Genomic DNA from six responders (two RARS, two RCMD, two
RCMD-RS) and six nonresponders (three RARS, two RCMD, one
RCMD-RS) were analyzed by CGH. Copy number variations have
been detected in six patients, gains in four patients at chr2q33.1,
6q26, 7q34 and 17q25.3, a deletion of chr11 in one patient (also
detected by the karyotype analysis) and a micro-deletion at
chr10q21 in one patient. No deletion/gain of the 3p26.2 region
has been identified. Furthermore, the regions encoding for CRBN
putative partners (DDB1, DDB2, CUL4A, CUL4B, RBX1, DCAF4L1,
DCAF4L2, DCAF5, DCAF6, DCAF7, DCAF8, DCAF8L1, DCAF10,
DCAF11, DCAF12, DCAF12L1, DCAF12L2, DCAF13, DCAF15, DCAF16,
DCAF17, DDA1 and RP11-574F21.3) were normal.
CRBN gene entire coding sequence and part of the promoter
region upstream the 50-untranslated region were sequenced in 12
patients including 6 responders and 6 nonresponders. We found no
nucleotide changes in the coding sequence except for a synon-
ymous change at nucleotide 3197918 in exon 6 corresponding to
tyrosine 244 in one case. Then, we analyzed the distribution of the
A/G polymorphism located at  29 nt of the 50-untranslated region
(located on chr3 at nt 3221430 and referenced as rs1672753).
According to public databases (ucsc.genome.edu), the A allele is
described as the ancestral allele from shrimp to human, although
Table 1. Characteristics of 51 low/int-1 MDS patients without del(5)q and treated by lenalidomide
UPN Age (years) WHO Karyotype IPSS HI-E CRBN (rs1672753)
2 76 RARS 46,XX low No A/A
4 75 RARS 46,XY low No A/G
5 70 RCMD-RS 46,XY low No A/A
15 62 RARS 46,XY int-1 No A/G
16 73 RARS 46,XY int-1 No A/A
21 66 RARS 46,XY low No A/A
22 68 RCMD-RS 46,XX int-1 No A/A
24 55 RARS 46,XX low No A/A
25 76 RARS 46,XX low No A/G
27 63 CMML 46,XY int-1 No A/A
34 73 RARS 46,XX low No A/A
36 63 RARS 46,XY int-1 No A/G
38 76 RAEB-1 46,XX int-1 No A/A
42 74 RARS 46,XX int-1 No A/A
45 64 RARS 46,XX low No A/A
46 70 RAEB-1 46,XX,del(11)q int-1 No A/G
48 70 RA 46,XY low No A/A
56 77 RCMD-RS 46,XY low No A/A
57 77 RA 46,XX low No A/A
61 67 RCMD 46,XY low No A/A
62 79 RARS 45,X,-Y low No A/G
63 76 RAEB-1 46,XY,del(12)(q21;q23-24) int-1 No A/G
67 62 RCMD 46,XY low No A/A
69 75 RA 46,XX low No A/A
70 80 RARS NA NA No A/A
73 62 RAEB-1 46,XY,del(20)(q11) int-1 No A/A
74 63 RARS 46,XY int-1 No A/A
75 75 RCMD 46,XY low No A/A
83 77 RCMD-RS 46,XY low No A/A
86 74 RCMD-RS 46,XX low No A/A
87 71 RAEB-1 46,XY int-1 No A/A
99 65 RARS 46,XY int-1 No A/A
106 79 RARS 46,XX low No A/A
111 72 RCMD-RS 46,XY low No A/A
118 54 RARS 46,XX int-1 No G/G
126 77 RARS 46,XY low No A/A
127 74 RARS 47,XY,þ 8 int-1 No A/G
7 74 RA 46,XX low Yes A/G
13 62 RCMD-RS 46,XY int-1 Yes A/G
39 62 RARS 46,XY int-1 Yes A/G
54 80 RCMD 47,XY,þ 8 int-1 Yes A/A
93 77 RCMD 47,XX,del(11)q,þ 8 int-1 Yes A/G
114 77 RCMD 46,XY low Yes A/A
121 89 RCMD-RS 46,XY low Yes A/G
132 73 RARS 46,XY int-1 Yes A/A
33 72 RCMD 46,XY int-1 Yes A/G
103 68 RARS 47,XY,þ 8 int-1 Yes A/G
110 69 RARS 47,XY,þ 8 int-1 Yes A/A
116 54 RARS 46,XX low Yes A/A
123 74 RARS 46,XY low Yes A/A
130 74 RARS 46,XY low Yes A/G
Abbreviations: CMML, chronic myelomonocytic leukemia; HI-E, hematological improvement-erythroid; IPSS, International Prognostic Scoring System; int-1,
intermediate-1; NA, not available; RA, refractory anemia; RAEB-1, refractory anemia with excess blasts type 1; RARS, RA with ringed sideroblasts; RCMD,
refractory cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ringed sideroblasts; UPN, unique patient number. The response to lenalidomide was
evaluated according to IWG 2006 (HI-E: yes/no), after four cycles (n¼ 46) or after three cycles of treatment (underlined UPN, patient n¼ 5).
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the G allele is notified as the reference allele. This GC-rich region
was amplified as a 448-pb PCR product using the following primers:
CRBN1F: 50-GCAGGCCTGTAATTGTCCCT-30 and CRBN1R: 50-GCAA-
CAGAGCAGCGAAGAAA-30 in a GC-rich buffer as PCR mix.
The distribution of A and G alleles in our cohort (67% and 33%,
respectively) was not statistically different (P¼ 0.095) from that of
the general population as described (75.3% and 24.7%, respectively)
in ucsc.genome.edu.
We then analyzed the impact of this CRBN A/G polymorphism
according to the response to lenalidomide in low/int-1 MDS
patients without del(5q). We found that 8 (57%) of the 14
responders had the G allele (all A/G) versus 9 (24%) of the 37
nonresponders (one G/G and 8 A/G). The crude odds ratio for
response to treatment in the G allele group with reference to the
A allele group was equal to 4.14 (95% confidence interval: 1.17–
14.76), thus significantly different from 1 (P¼ 0.045). In order to
investigate potential confusion bias, differences for clinical and
hematological characteristics between the G and the A allele
groups were studied. No sex (P¼ 0.674) or age (P¼ 0.624)
difference was found, and a trend (P¼ 0.057) for an increased
proportion of int-1 IPSS status in the G allele group (11/17¼ 64%)
compared with the A allele group (12/33¼ 36%) was observed.
This suggests that the best response rate in the group of patients
with G allele is not linked to a more favorable IPSS.
Among the 51 patients of our cohort, bone marrow mononuclear
cell RNA was available before treatment for 36 patients (22
nonresponders and 14 responders). CRBN gene expression level
was analyzed by using an reverse transcriptase quantitative PCR
strategy. The primers (CRBN_F in exon 7: 50-CAAGAAACAGCTACGT
GAATGG-30, CRBN_R in exon 8: 50-GAAGTCGCTGGATAGCACTG)-30
allowed the detection of the full-length transcript (NM_016302.3)
and two other transcripts including CRBN-002, whose upregulation
is predictive of the response to thalidomide in myeloma.12
Normalized relative quantities were calculated by using ACTIN,
HPRT1 and UBC as reference genes. No statistical difference in the
CRBN gene expression level was observed between responders and
nonresponders. Although the rs1672753 polymorphism was
located within a target region for transcription factors, the G
allele (n¼ 12) was not associated with a different level of CRBN
mRNA in comparison to the A allele (n¼ 24). These preliminary data
indicate that, unlike current observation in myeloma, the CRBN
expression level does not seem to be involved in the mechanism of
response to lenalidomide in low/int-1 MDS without del(5)q.
In this study, we have identified a relevant molecular biomarker
that could predict the response to lenalidomide in low/int-1 MDS
without del(5q). Previous studies showed that a favorable
karyotype or a molecular signature consisting of a set of
downregulated erythroid-specific genes is predictive of response
in these patients.13,14 Although IMiDs directly inhibit CRBN, we
could not exclude that these drugs may target other molecules,
notably in MDS with del(5q). Indeed, secondary resistance to
lenalidomide in MDS with del(5q) was found to be associated with
overexpression of CDC25C.15 Further studies are required in larger
cohorts to confirm our findings and to investigate the biological
consequences of CRBN polymorphism.
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Biologique, Hôpitaux Universitaires Paris Centre,
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Loss of Tcf 7 diminishes hematopoietic stem/progenitor cell
function
Leukemia (2013) 27, 1613–1614; doi:10.1038/leu.2012.354
The canonical Wnt-b-catenin pathway is an evolutionarily
conserved and tightly regulated pathway in development.
Activation of this pathway occurs upon binding of a soluble Wnt
protein to a membrane-associated receptor, and leads to the
disruption and inhibition of a protein complex responsible for the
phosphorylation and breakdown of b-catenin. Inhibition of this so-
called destruction complex, composed of the tumor suppressor
Apc, the Ser-Thr kinases Gsk-3b and CK-I, and the scaffold and
tumor suppressor protein Axin, results in stabilization and
(nuclear) accumulation of b-catenin. Stabilized b-catenin forms a
bipartite transcription factor with the Tcf-Lef family of transcrip-
tion factors (including Tcf7, Tcf7l1, Tcf7l2 and Lef1) to activate a
Wnt-controlled gene expression program.1
In the hematopoietic system, a role for Wnt signaling was
first demonstrated during T-cell development in the thymus.2
Subsequently, opposing effects of Wnt signaling on
hematopoiesis have been reported. For example, Mx-Cre-
mediated deletion of b- or b- and g-catenin did not effect
hematopoiesis, but stabilized forms of b-catenin resulted in either
enhancement of hematopoietic stem cell (HSC) function and
maintenance of an immature phenotype or exhaustion of the
HSC pool.3–8 These differences might be explained by different
levels of Wnt pathway activation. By using various targeted
hypomorphic Apc alleles and a conditional deletion allele of Apc,
which generates different Wnt signaling levels, it has been shown
that different, lineage-specific Wnt dosages regulate HSCs, myeloid
precursors and T lymphoid precursors during hematopoiesis.9
The Tcf7 gene is a complex gene of which several different
isoforms, including isoforms that lack the b-catenin binding
domain, have been found. Tcf7 has been reported to be a
b-catenin-Tcf7l2 target gene and to act as a feedback repressor of
b-catenin-Tcf7l2 target genes. In this way, Tcf7 may assist Apc to
suppress malignant transformation of epithelial cells.10 Tcf7
expression is most abundantly expressed in T-lymphocytes, but
is also expressed in HSCs.11,12 B6-Tcf7-deficient mice develop a
progressive block in the early thymocyte development, but are
fully immunocompetent and live for over 1 year.2,13 Here, we
report the impact of loss of Tcf7 on HSC and progenitor cells









































































Figure 1. Comparison of LSK frequency and functionality in vitro an
in vivo between WT and B6Tcf7/ mice. (a) BM cellularity and LSK
frequency (pooled from three mice). BM cells (b) and purified LSK (c)
were plated in CAFC cultures, and CAFC frequency was determined
at different culture times. (d) In vivo functionality of unseparated BM
cells (2 million) transplanted in competition with normal BM cells
(1 million). The percentage of donor chimerism was determined in
blood on nucleated blood cells by flow cytometry and the % donor
chimerism was calculated (% donor/(% donorþ % competitor)).
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